Vol. 2 No. 11 (2022)
Reimbursement Recommendations

Entrectinib (Rozlytrek)

Published November 21, 2022

Key Messages

  • CADTH recommends that Rozlytrek be reimbursed by public drug plans for the treatment of adults with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation if certain conditions are met.
  • Rozlytrek should only be reimbursed to treat patients who have previously failed on all standard treatments for their current tumour site and who will be able to tolerate the treatment.
  • Rozlytrek should only be reimbursed as a single-agent therapy and should not be initiated in patients who have primary CNS tumours or those who have received prior treatment with an NTRK inhibitor.